Press release
Precision Meets Affordability, Ace Therapeutics Unveils In Vivo Efficacy Testing Services for IBD Drug Candidates
IBD Mouse Models
Ace Therapeutics, a preclinical contract research provider, announced recently that it haslaunched in vivo efficacy testing services for IBD drug candidates. Building on in vitro successes to translate into clinical advances, the services meld state-of-the-art precision with affordable solutions that enable biotech and pharmaceutical organizations to expedite their IBD drug discovery efforts.
In vivo efficacy studies are an important milestone in innovative drug development and a key limitingfactor for downstream development. Given how challenging IBD research is, from the complex nature of disease mechanisms to the requirement fora sound preclinical data pack, Ace Therapeutics has developed a full suite of validated preclinical IBD drug testing services [https://www.acetherapeutics.com/ibd/in-vivo-efficacy-testing-of-ibd-drugs.html] based on well-validated animal models - and featuring state-of-the-art analytical options.
Comprehensive Animal Models for Unmatched Relevance
Ace Therapeutics offers a diverse portfolio of IBD animal models to suit every research need, including:
l Chemical-induced models (such as the DSS-induced colitis model);
l T cell transfer models;
l Genetically engineered models.
Each model is rigorously maintained to ensure reproducibility, providing clients with biologically relevant data that reflects real-world disease pathology.
All-Inclusive Efficacy Assessment Capabilities
To deliver a holistic view of drug performance, the services include a full spectrum of evaluations:
l Disease Activity Index (DAI) scoring;
l Colon length and weight analysis;
l In vivo colonoscopy;
l Histological and immunohistochemical evaluation of intestinal tissue;
l Inflammatory marker assessment (via ELISA, MSD, Luminex, CBA, and more);
l Oxidative stress marker detection;
l Intestinal permeability measurement;
l Myeloperoxidase (MPO) analysis in colon tissue;
Speed, Customization, and Affordability-Core to the Offering
Ace Therapeutics' in vivo efficacy testing for IBD is engineered to streamline drug development without compromising quality:
l Rapid study start-up: Accelerates timelines to keep drug candidates on track;
l Tailored study designs: Each project is customized to align with clients' specific research goals, whether for proof-of-concept or therapeutic efficacy validation;
l Integrated research platforms: Seamlessly combines in vivo imaging, biomarker analysis, flow cytometry, and histopathology to eliminate workflow bottlenecks;
l Actionable reports: Fast, reproducible data is delivered in detailed, client-specific reports, unlocking insights into disease mechanisms and treatment potential;
l Affordable access: Breaks down cost barriers, making high-quality preclinical testing accessible to small biotechs, large pharma, and academic researchers alike.
"We understand that advancing an IBD drug candidate requires both precision and efficiency-every data point matters, and time is of the essence," said the business development manager at Ace Therapeutics. "Our in vivo efficacy testing services are designed to deliver reliable, actionable results at a competitive price point, empowering our clients to make confident decisions as they progress toward clinical trials. With our expertise in IBD models [https://www.acetherapeutics.com/ibd/customized-ibd-models.html] and analytical techniques, we're proud to be a partner in the fight against this debilitating disease."
About Ace Therapeutics
Ace Therapeutics is a trusted provider of preclinical drug development services, specializing in efficacy testing for complex diseases. With a team of experienced researchers and state-of-the-art facilities, the company delivers customized, reliable solutions to advance scientific discovery and accelerate the path from lab to clinic.
Media Contact
Company Name: Ace Therapeutics
Contact Person: Daisy Mostert
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=precision-meets-affordability-ace-therapeutics-unveils-in-vivo-efficacy-testing-services-for-ibd-drug-candidates]
Phone: 1 516 441 0167
Country: United States
Website: https://www.acetherapeutics.com/ibd/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Precision Meets Affordability, Ace Therapeutics Unveils In Vivo Efficacy Testing Services for IBD Drug Candidates here
News-ID: 4323306 • Views: …
More Releases from ABNewswire
How Retailers Use Digital Catalogs to Increase Conversion Rates
Conversion rates indicate what percentage of visitors go through with purchases, and even minor increments essentially mean huge revenue gain. A retailer who typically converts only 2% of the traffic but manages to increase that to 2.5% will have grown his revenue by 25% without any additional visitors. Digital catalogs have become a great tool of conversion as they directly deal with the specific issues that prevent a buyer from…
This $6 AI Leprechaun Video Is Replacing the St. Patrick's Day Card as the Funni …
LeprechaunVideo.com launches an AI-powered video greeting service that transforms any selfie into a personalized talking leprechaun with an Irish accent, original comedy script and Celtic music for $5.99 - positioning itself as the modern alternative to the traditional St. Patrick's Day card.
BATH, England - Feb 23, 2026 - LeprechaunVideo.com today launched an AI-powered video greeting service that transforms a selfie into a personalized talking leprechaun, giving anyone a funnier way…
Sure Way Cash introduces online loan service for installment loans up to $10,000
Chicago, IL - Sure Way Cash [https://www.surewaycash.com/] today announced the launch of its online loan connector service that allows U.S. residents to check installment loan options up to $10,000 through a secure request process without a hard credit check.
The platform is designed for borrowers who may have bad credit, limited credit history, or prior loan denials and want to explore loan options without upfront fees or obligation. Users can submit…
Otter Public Relations Awarded in the Excellence in Workplace Culture Award for …
ST. PETERSBURG, Fla. - Feb 23, 2026 - Otter Public Relations [https://otterpr.com/]was proudly awarded Excellence in Workplace Culture for Small Businesses for 2025.
Otter PR, founded by Scott Bartnick and Jay Feldman, is one of the nation's most highly rated and awarded PR firms. With over 300 years of combined experience, Otter PR is known for results-driven campaigns and securing valuable media coverage. Otter PR's team of publicists, writers, marketers, and…
More Releases for IBD
Ace Therapeutics Unveils Imaging Services for Precise Characterization of IBD An …
Ace Therapeutics launched its translational imaging services specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models.
New York, USA - May 28, 2025 - Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies.
Image: https://www.getnews.info/uploads/3c0755ac659fa5075e809ffd1b893496.jpg
Imaging techniques play a crucial…
Inflammatory Bowel Disease (IBD) Market Size, Growth Insights, and Future Trends
Inflammatory Bowel Disease (IBD) continues to pose significant challenges for individuals and healthcare systems worldwide. With its increasing prevalence, the demand for effective treatments is driving market growth. The IBD treatment market is projected to grow from USD 19.91 billion in 2023 to USD 33.19 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period.
Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5149
Key Market Highlights
• Crohn's Disease Dominates: Crohn's disease…
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,…
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios.
Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx…
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per…
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and…
